A Phase 3, Open Label Trial Evaluating The Safety, Tolerability And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Healthy Children Aged 15 Months To 17 Years In Us.
A Phase 3, Open Label Trial Evaluating The Safety, Tolerability And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Healthy Children Aged 15 Months To 17 Years In Us.
This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.
Inclusion Criteria:
Group 4 only:
Exclusion Criteria:
Group 4 only: